

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HATCHER GROUP LIMITED

亦辰集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8365)

VOLUNTARY ANNOUNCEMENT INVESTMENT IN NEW BUSINESS

This announcement is made by Hatcher Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep its shareholders and potential investors informed of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 28 September 2026, the Company (the “**Purchaser**”) and Vast Gain Ltd. (the “**Vendor**”) entered into a sale and purchase agreement (the “**SP Agreement**”), pursuant to which the Company agreed to acquire 51% of the issued share capital of Advanced Meditech Force (HK) Limited (the “**Target Company**”) (the “**Acquisition**”).

The Target Company is a company incorporated in Hong Kong with limited liability and principally engaged in the operation of cancer screening and early detection centre, artificial intelligence (“**AI**”) driven digital pathology, and the provision of turnkey solutions for cancer diagnosis and treatment. As at the date of this announcement, the Target Company is wholly and beneficially owned by the Vendor.

The obligations of the Purchaser and the Vendor under the SP Agreement include the following:

As the majority shareholder of the Target Company following completion of the Acquisition, the Purchaser shall:

- (i) assist the Target Company in fund-raising activities; and
- (ii) provide or arrange the provision of related services like accounting, corporate secretarial and corporate finance services to the Target Company.

The Vendor shall use its best endeavor to assist the Target Company in establishing a cancer screening and early detection centre, along with the promotion and operational site deployment of AI-driven digital pathology, and the provision of turnkey solutions for cancer diagnosis and treatment.

Precision oncology and digital pathology are vital growth areas in contemporary medical technology, driven by a dual-engine diagnostic platform that integrates liquid biopsy with AI-driven digital pathology. According to market analysis, the global cancer diagnostics market is projected to reach US\$6 billion by 2030, representing a compound annual growth rate (“CAGR”) of approximately 6.7%, while the digital pathology market is expected to reach US\$1.5 billion, representing a CAGR of approximately 8.6%. Currently, healthcare systems globally, such as the National Health Service (NHS) of the United Kingdom, are facing significant gaps characterized by strained pathology capacity and an urgent need to improve early diagnosis rates. The Target Company’s core technology provides non-invasive, earlier, and faster comprehensive intact live-cell detection. Coupled with AI-assisted image analysis, this solution effectively addresses the critical pain points of existing healthcare systems.

In view of these and based on assessments by the Directors, the Board believes that investing in precision medicine and AI-driven digital pathology business not only aligns with the substantial global healthcare market demand, but also can diversify the Group’s sources of revenue, thereby creating long-term value for the Group and its shareholders.

As all of the applicable percentage ratios in respect of the Acquisition are less than 5%, the Acquisition therefore does not constitute a notifiable transaction of the Company under Chapter 19 of the Rules Governing the Listing of Securities on GEM (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). This announcement is made by the Company on a voluntary basis. The Company will make further announcement(s) in relation to the above as and when appropriate in accordance with the GEM Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Hatcher Group Limited
Hui Ringo Wing Kun
Executive Director

Hong Kong, 28 September 2026

As at the date of this announcement, the Directors are:

Executive Directors:

Mr. Li Man Keung Edwin (*Executive Chairman*)

Mr. Hui Ringo Wing Kun

Mr. Yeung Chun Yue David (*Vice Chairman*)

Non-executive Director:

Ms. Chan Hiu Shan

Independent Non-executive Directors:

Mr. William Robert Majcher

Mr. Ho Lik Kwan Luke

Mr. Lau Pak Kin Patric

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the Stock Exchange’s website at www.hkexnews.hk for at least 7 days from the date of its publication and will be published on the Company’s website at www.hatcher-group.com.

* for identification purpose only